The Effect of GIP(3-30)NH2
Not Applicable
Completed
- Conditions
- Endocrine - Other
- Interventions
- Other: GIP receptor antagonistOther: GIP receptor agonistOther: Saline
- Registration Number
- NCT03770910
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Brief Summary
Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.
- Detailed Description
Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.
Six study hyperglycemic clamps (10 mmol/l) pr. participant.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 8
Inclusion Criteria
- Healthy
- BMI 19-28 kg/m*m
- Stable body weight
Exclusion Criteria
- Diabetes
- Anemia
- First-degree relatives with diabetes
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description GIP+dose4 GIP receptor agonist GIP(1-42) and highest dose of GIP(3-30)NH2 GIP+placebo Saline GIP(1-42), receptor agonist GIP+dose 1 GIP receptor agonist GIP(1-42) and lowest dose of GIP(3-30)NH2 Placebo+placebo Saline Saline infusions GIP+dose 3 GIP receptor antagonist GIP(1-42) and dose of GIP(3-30)NH2 GIP+placebo GIP receptor agonist GIP(1-42), receptor agonist GIP+dose 1 GIP receptor antagonist GIP(1-42) and lowest dose of GIP(3-30)NH2 GIP+dose 2 GIP receptor antagonist GIP(1-42) and dose of GIP(3-30)NH2 GIP+dose 2 GIP receptor agonist GIP(1-42) and dose of GIP(3-30)NH2 GIP+dose 3 GIP receptor agonist GIP(1-42) and dose of GIP(3-30)NH2 GIP+dose4 GIP receptor antagonist GIP(1-42) and highest dose of GIP(3-30)NH2
- Primary Outcome Measures
Name Time Method Insulin secretion 8 weeks Insulin secretion rates (ISR) calculated from serum levels of C-peptide
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Clinical Metabolic Physiology
🇩🇰Copenhagen, Gentofte, Denmark